FINWIRES · TerminalLIVE
FINWIRES

TSX指数は正午時点で200ポイント下落、全セクターが下落

By

-- トロント証券取引所は正午時点で約200ポイント下落し、全セクターがマイナス圏に沈んでいる。 鉱業セクターとエネルギーセクターはそれぞれ1.8%と1.3%下落し、最もパフォーマンスが悪い。 イランがホルムズ海峡を航行中の米軍艦艇をミサイル2発で攻撃したと主張したことを受け、原油価格は月曜早朝、不安定な取引の中で上昇した。報道によると、米中央軍はこの主張を否定している。もし実際に攻撃があったとすれば、両国間の停戦協定が破棄される可能性もある。 金価格は月曜早朝、ドル高と利回り上昇を受けて下落したが、過去1ヶ月間維持してきた狭いレンジ内で推移している。 その他のニュースとして、CIBCは、2月28日にイラン紛争が始まって以来、肥料・化学関連株が概ね好調で、平均約14%上昇していると指摘している。これは、同時期のS&P500指数の5%上昇、TSX総合指数の1%下落と比較すると、対照的な動きと言える。 中東紛争が貿易の流れを混乱させ続ける中、肥料とメタノールの商品市場は先週、比較的低調だった。アナリストのハミル・パテル氏によると、米国の肥料価格は購買力に見合わない水準に達しているようで、買い手の関心も差し迫った需要よりも夏・秋の在庫補充需要に大きくシフトしているという。

Related Articles

Sectors

Update: Gold Falls as the Dollar and Yields Climb

(Updates prices.)Gold traded lower midafternoon Monday as the dollar and yields rose, forcing the precious metal below the tight range it has stuck within for the past month.Gold for June delivery was last seen down US$112.20 to US$4,533.20 per ounce, the lowest since March 27.The war on Iran has prompted some safe-haven demand for the metal, even as the higher oil prices that followed the start of the war on Iran is hiking inflation. This is raising concerns higher interest rates are on the way, which is bearish for the metal since it pays no interest."Gold remains supported by safe-haven demand as investors continue to watch the Middle East conflict, oil prices, and the yen. Any durable easing in the Strait of Hormuz would likely cool demand for defensive assets, but until shipping flows normalise, gold should remain sensitive to geopolitical headlines and shifts in real yields," Saxo Bank noted.The dollar rose, with the ICE dollar index last seen up 0.2.9 points to 98.45. Treasury yields were sharply higher, with the U.S. two-year note last seen paying 3.975%, up 8.3 basis points, while the yield on the 10-year note as up 7.0 points to 4.449%

$GCM6$GLD
Australia

Top Midday Gainers

Celcuity (CELC) reported late Friday positive topline results from a cohort of its phase 3 Viktoria-1 trial, with the study meeting its primary endpoint and showing a clinically meaningful improvement in progression-free survival.The study evaluated gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer who had progressed after a CDK4/6 inhibitor and an aromatase inhibitor.Shares jumped more than 16%, with intraday trading volume at over 2.5 million from a daily average of roughly 737,000.CNS Pharmaceuticals (CNSP) shares surged 268% amid heavy trading after the company said Monday it signed deals for a private placement financing likely to generate roughly $22.5 million.Intraday trading volume catapulted to over 78.4 million shares from a daily average of about 32,000.American Express Global Business Travel, which is operated by Global Business Travel Group (GBTG), said Monday it has entered into a definitive agreement to be acquired by Long Lake Management for $9.50 per share in an all-cash deal valued at about $6.3 billion.Shares soared 57%, with intraday trading volume of over 61.6 million from a daily average of about 1.6 million.Price: $146.00, Change: $+20.35, Percent Change: +16.20%

$CELC$CNSP$GBTG
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.

$AMGN$LLY$MRNA$VNDA